Corvus Pharmaceuticals (CRVS): This Clinical-Stage Drugmaker Just Got A Lot More Interesting
On August 6, Corvus Pharmaceuticals (NASDAQ:CRVS) held its second-quarter 2026 earnings call, and the story was almost entirely about one molecule.
Corvus Pharmaceuticals Inc. (CRVS)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | OrbiMed Advisors Samuel Isaly | 7,165,006 | $107,045,190 | 1.98% | |
| 2. | Adams Street Partners Jeffrey Diehl | 3,275,616 | $48,937,703 | 11.06% | |
| 3. | Vivo Capital Albert Cha And Frank Kung | 2,805,816 | $41,918,891 | 3.83% | |
| 4. | Perceptive Advisors Joseph Edelman | 2,667,441 | $39,851,569 | +17% | 0.6% |
| 5. | Deep Track Capital David Kroin | 2,491,939 | $37,229,569 | +1% | 0.54% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $11.53 | 21,700 | $250,235.72 | 21,700 | 2026-06-11 | Filing | |
| $12.01 | 1,932 | $23,203.32 | 1,195,035 | 2026-05-18 | Filing | |
| $12.05 | 5,000 | $60,250.00 | 1,193,103 | 2026-05-18 | Filing | |
| $1.73 | 20,000 | $34,624.00 | 153,773 | 2024-05-06 | Filing | |
| $1.73 | 577,634 | $999,999.98 | 577,634 | 2024-05-06 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $4.16 | 1,176,332 | $4,891,894.26 | 7,165,006 | 2025-06-27 | Filing | |
| $4.16 | 1,176,332 | $4,891,894.26 | 7,165,006 | 2025-06-27 | Filing | |
| $4.96 | 2,000,000 | $9,928,800.00 | 81,077 | 2021-10-01 | Filing | |
| $5.04 | 3,000,000 | $15,131,100.00 | 2,081,077 | 2021-09-30 | Filing | |
| $6.09 | 1,109,644 | $6,757,731.96 | 6,943,654 | 2021-09-20 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 7,138,811 | $106,653,837 | 0% | |
| 2. | 4,474,091 | $66,842,920 | 0% | |
| 3. | 3,292,710 | $49,193,087 | 0% | |
| 4. | 2,731,632 | $40,810,581 | 0.01% | |
| 5. | 1,853,659 | $27,700,900 | 0% |
News See All
Is Corvus Pharmaceuticals, Inc. (CRVS) A Good Stock To Buy Now?
Is CRVS a good stock to buy? We came across a bullish thesis on Corvus Pharmaceuticals, Inc. on Biotech Distilled’s Substack. In this article, we will summarize the bulls’ thesis on CRVS.
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q4 2025 Earnings Call Transcript
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q4 2025 Earnings Call Transcript March 12, 2026Corvus Pharmaceuticals, Inc. misses on earnings expectations.
Corvus Pharmaceuticals (CRVS) Falls on Profit-Taking After 212% Jump
We recently published 10 Big Names Stumbling Hard. Corvus Pharmaceuticals Inc. (NASDAQ:CRVS) was one of the worst performers on Monday.
Corvus Pharmaceuticals (CRVS) Soars 212% on Impressive Eczema Therapy Study
We recently published 10 Stocks With Effortless Double-, Triple-Digit Gains. Corvus Pharmaceuticals Inc. (NASDAQ:CRVS) was one of the top performers last week.
Corvus Pharmaceuticals (CRVS) Hits All-Time High on Eczema Trial Results
We recently published 10 Stocks Delivering Double-Digit Gains Effortlessly; 4 Hit Highs. Corvus Pharmaceuticals Inc. (NASDAQ:CRVS) was one of the best performers on Thursday.
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q3 2025 Earnings Call Transcript
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q3 2025 Earnings Call Transcript November 4, 2025Corvus Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-0.12, expectations were $-0.14.
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q2 2025 Earnings Call Transcript
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q2 2025 Earnings Call Transcript August 8, 2025 Operator: Good afternoon, everyone.
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q1 2025 Earnings Call Transcript
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q1 2025 Earnings Call Transcript May 8, 2025Corvus Pharmaceuticals, Inc. reports earnings inline with expectations.
10 Low Risk High Reward Stocks Set to Triple by 2030
In this article, we will discuss 10 Low Risk High Reward Stocks Set to Triple by 2030.
Hedge Fund Resource Center